A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback